Sorry, you need to enable JavaScript to visit this website.
Investors
Notice Regarding the Discontinuation of Rocatinlimab Clinical Trials
March 03, 2026
サブ-ナビゲーション
Management
Top message
Vision 2030 and Beyond: Our Growth Story
Corporate Governance
Business Risk Factors
Financial Data
Key Financial Data
Key Financial Ratios
Cash Flow Data
Financial Tear Sheet
Reports & Presentations
Financial Results
Investor Events
Corporate Profile
Integrated Report
Securities
Investor Calendar
Stock & Rating
Stock Chart
Share Data
Dividends
Shareholders´ Meeting
Articles of Incorporation
Analyst Coverage
Bonds & Ratings
E-mail Alerts
Contact Us/Investors
Disclaimer
Disclosure Policy
Notice Regarding the Discontinuation of Rocatinlimab Clinical Trials
March 03, 2026